sglt2 inhibitors and glp 1 receptor agonists GLP-1 in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy | Drugs Frontiers | GLP−1 receptor agonists
Description
The effects of DPP4 inhibitors on the immune system are not well understood
This has the possibility of setting up a two-tier system whereby people who cant afford the more expensive drugs are only able to use drugs with less strong evidence of benefit, Krumholz said
Routine bone density scanning is not recommended based solely on GLP-1 use
Clinical trials show retatrutide can reduce body weight by up to 24% after 48 weeks, significantly outperforming many current obesity treatments
Resting heart rate increased by about 5-10 bpm on average and eased over time
Initiation of a GLP-1 receptor agonist was associated with reduced risk of composite endpoint of all SUDs (hazard ratio 0.86 (0.83 to 0.88), NRD 6.61 (7.95 to 5.26)) (fig 3, fig 4 and supplementary table S6)
